Niihara International Announces Launch of Corp. Website and SEC Qualification of Reg. A Offering

Niihara International, Inc. has launched a new corporate website and received SEC qualification of its Regulation A+ Tier 2 offering to support development and commercialization of therapies, including L‑glutamine for sickle cell disease and other unmet medical needs.

Niihara International Website & SEC Offering Update

Irvine, California, United States, 21st May 2026– Niihara International, Inc. (“Niihara International” or the “Company”), today announced the launch of its new corporate website at www.niiharainternational.com and the qualification by the U.S. Securities and Exchange Commission (“SEC”) of the Company’s Regulation A+ Tier 2 offering of common stock. The Company is a pharmaceutical access company focused on expanding access to proven therapies for serious and underserved medical conditions.

The new website is designed to provide investors, patients, healthcare professionals, and other stakeholders with streamlined access to information about the Company’s business, product development plans, corporate governance and investor materials. The site features dedicated sections for corporate information, regulatory filings, and updates regarding Niihara International’s efforts to develop and commercialize innovative therapies, including its initial product candidate, a generic prescription-grade L‑glutamine oral powder for sickle cell disease.

Niihara International’s Regulation A+ Tier 2 offering has been qualified by the SEC pursuant to the Company’s Offering Circular, which is available on the SEC’s EDGAR system. Under the qualified offering, the Company is offering shares of its common stock on a “best efforts” basis, with the proceeds intended to fund product development, clinical, regulatory and commercialization activities, as well as general corporate purposes.

Niihara International Regulation A+ Offering Update

The Offering Circular and related information about the offering can be accessed by visiting the SEC’s website and searching for Niihara International, Inc. (CIK 0002062360) or via the Company’s own website via the link to its subscription portal provided below. Prospective investors are urged to carefully review the Offering Circular, including the section titled “Risk Factors,” and all other documents incorporated by reference before making any investment decision.

“This is an important milestone for Niihara International as we advance our strategy to develop and deliver therapies for patients with serious unmet medical needs,” said Founder and CEO Yutaka Niihara. “The launch of our new website and the qualification of our Regulation A+ Tier 2 offering provide a foundation to communicate more effectively with investors and partners as we seek to execute on our growth plans.”

The securities described in the Offering Circular are being offered pursuant to Regulation A under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of securities will be made only by means of the Offering Circular and related subscription materials.

About Niihara International, Inc.

Niihara International, Inc., incorporated in California in 2023, is a development-stage biopharmaceutical company focused on the development, commercialization and distribution of innovative therapies. The Company is also focused on expanding access to proven therapies for serious and underserved medical conditions.

The Company’s initial product is a generic prescription-grade L‑glutamine oral powder designed to reduce acute complications associated with sickle cell disease in patients ages five years and older. For more information, please visit www.niiharainternational.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the Company’s business strategy, development plans, product candidates, potential markets, and the anticipated use of proceeds of the Regulation A+ Tier 2 offering. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described under “Risk Factors” in the Offering Circular and in other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and Niihara International, Inc. undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date hereof.

Offering Portal Administrator

Glass Box Law, Inc.

Offering Portal Website:  https://glassboxlaw.com/portal/niihara-international-inc

Advancing Access to Essential Therapies for Patients with Unmet Medical Needs

Frequently Asked Questions (FAQs)

1. What is Niihara International, Inc.?

Niihara International, Inc. is a California-based biopharmaceutical company. In addition, it focuses on developing therapies for serious and underserved medical conditions. In particular, it works on treatments for sickle cell disease.

2. What major announcement did Niihara International make?

Recently, the company announced two major developments. First, it launched its new corporate website. In addition, it received SEC qualification for its Regulation A+ Tier 2 offering. This allows the company to raise capital by selling common stock.

3. What is the purpose of the new corporate website?

The new website serves multiple audiences. For example, it provides information for investors, patients, healthcare professionals, and stakeholders. In addition, it shares product details, regulatory updates, and corporate governance information.

4. What is Regulation A+ Tier 2 offering?

Regulation A+ Tier 2 is a framework created by the U.S. Securities and Exchange Commission. It allows eligible companies to raise funds from the public. However, companies must still follow strict disclosure and reporting requirements.

5. How will Niihara International use the funds raised?

The company plans to use the funds in several ways. First, it will support product development and clinical research. In addition, it will fund regulatory work, commercialization efforts, and general corporate operations.

6. What is the company’s main product candidate?

Niihara International’s main product candidate is a generic prescription-grade L-glutamine oral powder. The company develops it to reduce complications in patients with sickle cell disease.

7. What condition is the product mainly targeting?

The product mainly targets sickle cell disease. This condition affects red blood cells. As a result, it can cause pain and other severe health complications.

8. Who can access information about the SEC offering?

Prospective investors can access full details about the offering. In addition, they can review the Offering Circular through the U.S. SEC EDGAR system. Alternatively, they can visit the company’s official website before making investment decisions.

9. What did the CEO say about the announcement?

Founder and CEO Yutaka Niihara shared his view on the update. He said the website launch and SEC qualification mark an important milestone. Furthermore, he highlighted improved communication with investors. He also noted stronger support for the company’s growth strategy.

10. Does the press release guarantee investment returns?

No, it does not guarantee returns. The announcement includes forward-looking statements. Therefore, actual results may differ due to risks and uncertainties.

Company Details

Organization: Niihara International, Inc.

Contact Person: Maurice Bethea

Website: https://niiharainternational.com/

Email: mbethea@niiharainternational.com

City: Rolling Hills Estates

State: California

Country: United States

Release Id: 21052645263